Riboxin - instructions for use, dose, side effects, contraindications

Inosine is a derivative (nucleoside) of purine, a precursor of adenosine triphosphate (ATP). Refers to a group of drugs that stimulate metabolic processes.

Has antihypoxic and antiarrhythmic effect. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism under conditions of hypoxia and in the absence of ATP. Inosine activates the metabolism of pyruvic acid necessary to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, it has a positive effect on metabolic processes in the myocardium - it increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, as a result of which the stroke volume increases.The mechanism of antiarrhythmic action is not fully understood.

Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and mucous membrane of the gastrointestinal tract).

Pharmacokinetics:The drug is metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount is excreted by the kidneys.

Indications:

Complex treatment of myocardial infarction, coronary heart disease, cardiac arrhythmias caused by the use of cardiac glycosides, against myocardial dystrophy after infectious diseases.

Diseases of the liver (hepatitis, cirrhosis, fatty degeneration).

Operations on an isolated kidney (as a means of pharmacological protection in the short-term shutdown of the circulatory system of the operated organ).

Contraindications:

Individual intolerance to inosine or other derivatives of purine, as well as other components of the drug; gout; hyperuricemia; pregnancy; the period of breastfeeding; age to 18 years (efficacy and safety not established).

Carefully:

Renal failure.

Pregnancy and lactation:

The use of Riboxin during pregnancy and during breastfeeding is contraindicated.

There is no data on the penetration of inosine into breast milk, so if you need to use the drug during lactation, breastfeeding should be discontinued.

Dosing and Administration:

Intravenously slowly drip or drip (40-60 drops in 1 minute). Treatment is initiated by introducing 200 mg (10 ml of a 20 mg / ml) 1 times a day, then, with good tolerability, the dose was increased to 400 mg (20 ml of a solution of 20 mg / ml) 1-2 times a day. Duration of treatment is 10-15 days.

Jet injection of the drug is possible for acute heart rhythm disorders in a single dose of 200-400 mg (10-20 ml of a solution of 20 mg / ml).

For pharmacological protection of the kidneys subjected to ischemia, Riboxin is injected intravenously in a single dose of 1200 mg (60 ml of a solution of 20 mg / ml) 5-15 minutes before the compression of the renal artery, and then another 800 mg (40 ml of a solution of 20 mg / ml) immediately after the restoration of blood circulation.

For intravenous drip, a solution of the drug 20 mg / ml is diluted in a 5% solution of dextrose (glucose) or 0.9% solution of sodium chloride (up to 250 ml).

Side effects:

Allergic reactions: urticaria, skin itching, skin hyperemia (drug should be discarded).

Rarely: an increase in the concentration of uric acid to the blood, exacerbation of the gout current (with prolonged use).

Overdose:

Currently, there have been no cases of overdose.

Interaction:

When used simultaneously with cardiac glycosides, it can prevent the occurrence of arrhythmias, enhance the positive inotropic effect.

Immunosuppressants reduce the effect of inosine.

Special instructions:

Riboxin is not used for emergency correction of cardiac disorders.

In case of renal insufficiency, the use of the drug is possible only if, in the opinion of the doctor, the expected positive effect prevails over the possible risk from use.

During prolonged treatment, the concentration of uric acid in the blood and urine should be monitored.

When skin pruritus and skin flushing occur, treatment with the drug should be discarded.

Effect on the ability to drive transp. cf. and fur:Clinical data on the study of the effect of the drug on the ability to drive vehicles, mechanisms there.

Form release / dosage:

Solution for intravenous administration, 20 mg / ml.

Packaging:

5 ml into neutral glass ampoules.

5 ampoules per contour cell packaging from a polyvinylchloride (PVC) film or from a polyethylene terephthalate (PET) film.

1 or 2 contour squares with instructions for use and scarifier ampoule in a pack of cardboard.

5 or 10 ampoules together with the instruction for use and scarifier ampoule in a pack of cardboard with a corrugated liner.

When using ampoules with a dot or a ring of fracture, the scarifier is not inserted.

Packing for hospitals

For 4, 5 or 10 contour packagings together with instructions for use in an amount equal to the number of contoured cell packs, into a cardboard pack.

For 50 or 100 contour mesh packages together with instructions for use in an amount equal to the number of contour mesh packages, into a box of corrugated cardboard.

Storage conditions:

Store in a dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-003699

Date of registration:22.06.2016

Expiration Date:22.06.2021

The owner of the registration certificate:ELLARA, LTD. ELLARA, LTD. Russia

Manufacturer: & nbsp

ELLARA, LTD. Russia

Information update date: & nbsp17.08.2016

Illustrated instructions

Instructions

Riboxin (Riboxin)